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ess: hendriknolte@hotmSummary The aim of this study was to determine the extent of unawareness and
undertreatment of asthma and allergic rhinitis in an adolescent and adult population
in Copenhagen, Denmark.
Methods: Patients with asthma and rhinitis were recruited by a standardised asthma
and rhinitis screening questionnaire. Out of a random sample of 10,877 subjects aged
14–44 years, 1149 subjects were treated or reported symptoms of asthma or rhinitis
and agreed to participate. Those subjects were assessed on history, lung function
tests, and skin prick tests. Disease severity and optimal treatment were decided
according to the GINA and ARIA guidelines.
Results: A total of 726 participants suffered from asthma and/or allergic rhinitis.
Concomitant upper and lower airways disease was found in 47%. Seventy-five per
cent were allergic and 44% with a known allergy had been tested previously. Asthma
was undiagnosed and untreated in 50% of all the asthmatics. According to the
guideline recommendation, 76% of asthmatics were undertreated. Rhinitis was
undiagnosed in 32% of patients and 83% with moderate to severe rhinitis were
undertreated. Patient knowledge about self-care and education was low.
Conclusions: In this population a large proportion of patients were unaware of
having asthma or rhinitis. The pharmaceutical treatment and management practice
were inadequate. Our study emphasises the need for additional intervention.
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The incidence and prevalence of asthma and
allergy are increasing concomitantly with improve-
ments in the diagnosis, treatment, and under-
standing of the diseases.1–4 Identification of
patients with asthma has the potential to lessen
impairment in health and functional status and cutd.
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role in the development of asthma and rhinitis,
which are often chronic diseases. Patients with
allergies may report poorer job or school perfor-
mance and allergic rhinitis may interfere with
sleep, intellectual functioning and recreational
activities.8,9 Studies of randomly selected popula-
tions indicate that up to more than a third of
patients with rhinitis and asthma are undiagnosed
and suffer from symptoms of allergy and a decrease
in the quality of life.8,10–14 This prompted a range
of measures; guidelines, health promotion, patient
education, and public information. Such initiatives
should provide a unique environment for early
diagnosis and optimal treatment. We, therefore,
examined the current extent of unawareness and
undertreatment of patients with asthma and
allergic rhinitis after the above initiatives had been
put into practice.Material and methods
Screening population
In year 2000, a random population sample of 10,877
subjects aged 14–44 years (to minimise entry of
patients with COPD) living in Copenhagen, Den-
mark, was taken from the civil registration list. All
the subjects were sent a letter with an asthma and
rhinitis screening questionnaire comprising 20
questions adapted from the ACAAI screening pro-
gramme.15 Five thousand eight hundred forty-nine
(response rate: 54%) subjects responded to the
postal questionnaire. In the case of at least one
affirmative response concerning respiratory tract
symptoms or treatment, the subject was invited to
take part in the present survey. The local ethical
committee of Copenhagen, Denmark approved the
study. All the participants were told about the
study verbally and in writing and all patients,
parents/guardians gave their informed consent.
Study population
Altogether, 1149 (10.6%) subjects reported respira-
tory symptoms or treatment and were examined.
Each of the subjects was given a physical
examination and a disease-specific case history
was taken by a respiratory specialist. Participants
were asked not to use medication interfering with
the tests described below. Of the 1149 responders,
726 patients (314 male, 412 female) met the
current guideline criteria of asthma and/or allergic
rhinitis (‘‘doctor-diagnosed patients’’). In the re-maining 423 we could not confirm asthma or
allergic rhinitis; i.e., the majority had asthma
symptoms (e.g., cough), but no objective measure-
ments of reversible airways, and were thus con-
sidered non-asthmatics; a small number with lower
tract respiratory symptoms, such as shortness of
breath or cough, but not asthma, suffered from
sarcoidosis, chronic obstructive pulmonary disease,
and cardiac illness.
Patient history
All participants filled in a questionnaire concerning
their general health, respiratory and allergic
symptoms (in the preceding 4 weeks or at any time
in the past) and a questionnaire on their knowledge
about self-care, their current medication, and
smoking habits, referrals, and GP visits. Life time
tobacco exposure was calculated as pack years
(tobacco consumption [g/day]/20 duration of
smoking [years]). Height and weight were mea-
sured and the body mass index (BMI) was calculated
as ((weight [kg])/(height [m]2)).
In patients with asthma, the severity of asthma
(mild, mild persistent, moderate and severe) was
classified according to the GINA guidelines.16 In
addition, the severity of rhinitis was categorised in
accordance with ARIA guidelines.17
Pulmonary function test and methacholine
challenge test
Spirometry was done on a 7-L dry wedge spirometer
(Vitalographs) in accordance with the ERS recom-
mendations18 and the percentage of predicted
normal values was calculated. Airway responsive-
ness to inhaled methacholine was measured in
accordance with the method of Yan et al.19 in all
patients with a FEV1470%. The dose producing in a
20% fall in FEV1 (PD20) was calculated, and the
dose–response slope (DRS) calculated as the de-
cline in FEV1 divided by the highest dose of
methacholine given.20,21 A constant of 4 was added
to all dose–response slopes to eliminate negative
and zero values. Logarithmically transformed DRS
values were used for analysis. Measurement of the
FEV1 was repeated 15min after administration of
0.6mg of salbutamol.
Skin prick test
A skin prick test was performed in duplicate with an
ALK-Abello lancet with a 1-mm tip according to the
EAACI recommendation.22 Patients were tested
with 10 common inhalant allergens. A positive
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5mm to one or more allergens. Patients with
positive skin tests were considered atopic.Diagnosis of asthma
Asthma was diagnosed on both a combination of
respiratory symptoms (cough, chest tightness,
dyspnoe, wheeze) and reversible airway signs, i.e.
airway hyperresponsiveness (AHR) to inhaled
methacholine o4.0 mmol, or peakflow variability
420% over a period of 2 weeks (miniWrights Peak
Flow meter), or at least a 500ml increase in FEV1
after bronchodilator challenge. Patients were
considered asthmatics only, if one or several of
the above symptoms were confirmed by one of the
above tests. Subjects were asked, ‘‘Have you ever
been told that you suffer from asthma?’’ Those,
with no previous diagnosis, but with asthma-like
symptoms within 12 months of (written self-
reporting of symptoms) or 4 weeks before (physi-
cian-interviewed) the first visit were labelled
undiagnosed symptomatic asthmatics. At the time
of diagnosis, it was possible to assess from the
severity of the disease and current medication
whether patients were receiving optimal treat-
ment, as suggested by the GINA guideline.16Diagnosis of rhinitis
Allergic rhinitis was identified by symptoms of
rhinitis when patients were exposed to aeroaller-
gens and showed a positive allergen skin prick
test. The questionnaire concerning severity of
upper airway symptoms and definition of rhinitisTable 1 Patient characteristics (mean (SD)).
Asthma only Alle
No. 155 233
Gender (female) 67% 48%
Age 27.56 (9.6)* 29.
BMI 24.03 (4.4) 24.
FEV1 absolute 3.44 (0.8)** 3.9
FEV1% predicted 93.81 (16.8)** 98.
FVC 4.24 (1.1)** 4.7
FVC % predicted 96.44 (13.0) 97.
FEV1/FVC ratio 81.99 (9.5) 85.
Atopy (i.e. pos. allergy skin test) 21% 100
AHR logDRS 0.998 (0.4) 0.6
Never smokers 20% 34%
Current smokers 49% 33%
Pack years 7.98 (7.7) 6.5
#o0:05, Po0:01, Po0:001.
Airway hyperresponsiveness (AHR) (dose response slope (DRS))symptoms within the preceding 4 weeks (physician-
interviewed) or at any time (written self-reports)
were classified in accordance with ARIA guide-
lines.17 It was possible to assess from the disease
severity and current medication whether patients
were receiving optimal treatment, as suggested by
the ARIA guidelines.
Analysis
The data were analysed with the statistical pack,
SPSS for Windows. Frequencies were calculated for
the entire group and differences were tested by w2
analysis. Furthermore, differences in mean (7SD)
values between participants with and without
respiratory symptoms were tested by parametric
analysis (Student’s t-test). A P value o0.05 was
considered significant.Results
Patients’ characteristics
Of the 726 participants with a diagnosis of asthma
or allergic rhinitis, 493 (68%) were diagnosed as
having asthma with (n ¼ 338) or without rhinitis
(n ¼ 155) and 571 (79%) rhinitis with or without
asthma. One hundred and fifty-five (21%) had
asthma only and 233 (32%) allergic rhinitis only,
and 338 (47%) had both (Table 1). Of the asthma
patients, 69% (338/493) also had rhinitis, and of
those with rhinitis 59% (338/571) also suffered from
asthma. Patients with asthma only and those with
both asthma and rhinitis exhibited lower FEV1,rgic rhinitis only Asthma & rhinitis All
338 726
* 58% 57%
98 (8.8) 28.93 (9.1) 28.98 (9.2)
45 (5.1) 25.08 (5.3) 24.66 (5.1)
8 (0.8) 3.56 (0.8) 3.67 (0.8)
80 (12.5) 93.2 (14.8) 95.5 (14.9)
0 (1.0) 4.35 (1.0) 4.44 (1.0)
65 (12.7) 95.21 (14.3) 95.84 (14.3)
1 (6.2)** 82.00 (8.3) 83.0 (8.1)
% 83% 75%
90 (0.1)** 1.002 (0.4) 0.898 (0.4)
34% 31%
36% 38%
9 (7.9) 7.54 (8.8) 7.41 (8.3)
ARTICLE IN PRESS
Unawareness and undertreatment of asthma and allergic rhinitis 357compared with the rhinitis only patients
(Po0:001). Airway responsiveness was increased
in asthmatics, who demonstrated a significantly
higher logDRS than observed in patients with
rhinitis only (0.998 or 1.002 versus 0.69, Po0:001).
Altogether, 544 (75%) were sensitised to inhalant
allergens. Out of the 155 asthmatics, 32 (21%)
suffered from allergic asthma. Of the patients with
both asthma and rhinitis, 279 (83%) were sensitised.
The three most common sensitising allergens were
grass (44%), birch (31%), and cat (30%). Only 56% of
patients with allergic asthma had prior knowledge
of allergic sensitisation.Patients with undiagnosed asthma
At the time of enrolment the proportion of
undiagnosed (‘‘unaware’’) patients with asthma
was 67%.
The frequency of ‘‘mild intermittent’’, ‘‘mild
persistent’’, ‘‘moderate persistent’’, and ‘‘severe
persistent’’ asthma was 26%, 20%, 25%, and 29%,
respectively (Table 2). One hundred and eighty-six
(38%) patients with moderate to severe persistent
asthma (GINA 3–4) were unaware they had asthma
and were also untreated (see below). The differ-
ence in unawareness between those with mild
intermittent and mild persistent asthma and those
with severe asthma reached statistical significance
(Po0:05).Table 2 Asthma awareness and disease severity.
GINA 1 GINA 2
Diagnosed 43 (9%) 37 (8%)
Undiagnosed 85 (17%) 60 (12%)
Total 128 (26%) 97 (20%)
Asthma severity and awareness in 493 patients with doctor-diagn
according to GINA in four classes.
Table 3 Asthma severity and current treatment.
GINA 1 GIN
No treatment 88 61
Short-acting b2-agonist (SABA) 18 19
Long-acting b2-agonist (LABA) 1 1
Inhaled steroids 11 5
Inhaled steroid, SABA or LABA 10 11
Total 128 97
Asthma severity and anti-asthmatic treatment in 493 patients with
is classified according to GINA in 4 classes. One asthmatic receivAsthma treatment and disease severity
Most (62%) of the asthma patients were untreated
(Table 3). Inhaled corticosteroids were the most
commonly used drugs, but only 86 of 365 (24%)
patients requiring inhaled corticosteroids (GINA
2–4) were using them. Patients with severe
persistent asthma (GINA 4) received inhaled ster-
oids more frequently than the patients with less
disease severity (GINA 1–3).
The second most commonly used drug was b2-
agonists and long acting b2-agonists were rarely
used. Leukotriene modifiers were used by a few
patients. Only 26% of GINA 3–4 patients were taking
the recommended combination therapy (corticos-
teroid and b2-agonists). The ratio of inhaled
corticosteroid use to short-acting bronchodilators
was 40.7.
The total proportion of both undiagnosed and
untreated asthma patients was 50% (n ¼ 245).Influence of rhinitis and atopy on asthma
severity
We found no significant association between sever-
ity of asthma and the presence of rhinitis, although
those with moderate to severe asthma had allergic
rhinitis less often. The proportion of patients with
allergic rhinitis, GINA (class 1 to 4) was 77%, 70%,
63%, and 65%, respectively (P ¼ 0:09).GINA 3 GINA 4 Total
36 (7%) 46 (9%) 162 (33%)
89 (18%) 97 (20%) 331 (67%)
125 (25%) 143 (29%) 493 (100%)
osed asthma at the time of enrolment. Severity is classified
A 2 GINA 3 GINA 4 Total
79 75 303 (62%)
14 23 74 (15%)
3 4 9 (2%)
14 23 53 (11%)
15 18 54 (11%)
125 143 493
doctor-diagnosed asthma at the time of enrollment. Severity
ed immunotherapy in addition to pharmacotherapy.
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and education
Patients with an asthma diagnosis (with or without
rhinitis) before entering the study were asked
about their knowledge of asthma and treatment
principles. Almost half (48%) of the patients had
been instructed by their primary care physician on
how to use their asthma devices and 27% knew how
to use peak flow meters (Table 4). Less was known
about asthma triggering agents and how to avoid
them, and little about adjustment of asthma
medication. Only 1% had a written asthma manage-
ment plan. Forty per cent had been referred to a
specialist previously and 85% had seen their general
practitioner within the last year.Patients with undiagnosed rhinitis
Among the 571 patients with allergic rhinitis, 32%
(n ¼ 182) were undiagnosed (‘‘unaware’’) (Table
5). Of the previously diagnosed patients, 251 (44%)
were told they had a specific allergy to pets,
pollen, dust, or moulds. Thus, allergy had not been
diagnosed in 319 (56%) patients with allergic
rhinitis. Unawareness was slightly lower in theTable 4 Patients’ knowledge of asthma.
Have you been taught how to:
Use your asthma inhaler or device?
Use a peak flow meter?
Recognise asthma and rhinitis triggers and how to avoid t
Adjust your medication if you are exposed to asthma trigg
Adjust your medication when your asthma worsens or you
Do you have a written asthma management plan?
GP visits within the past year?
First visit to asthma specialist?
Response of previously diagnosed asthma patients (n ¼ 162) to
primary physician before the study. Responses of patients who
inhalation devices are given under N/A (not applicable. Patients
Table 5 Rhinitis awareness and disease severity.
Mild intermittent Mild persistent M
in
Diagnosed 134 43
Undiagnosed 65 34
Total 199 (35%) 77 (14%) 1
Severity of and awareness in 571 patients with physician-diagno
according to ARIA in 4 classes.mildly affected than in the moderate to severe
categories (Po0:01).Rhinitis treatment and disease severity
Table 6 shows the severity and treatment of
rhinitis. In 388 ‘‘doctor-diagnosed’’ patients, 19%
(n ¼ 72) were untreated and the rest used anti-
histamines as needed or combined with intranasal
corticosteroids (92%). In contrast, the majority
(75%) of the undiagnosed patients were untreated
(‘‘untreated and undiagnosed’’, 138/183) and 18%
took antihistamines or received other treatment. In
general, antihistamine was the most commonly
used medication. Intranasal corticosteroids were
used only by 16% of patients with moderate to
severe rhinitis. Immunotherapy treatment was rare
(2%).Undertreatment
According to recommendations for treatment in
international guidelines, most of the patients (82%,
n ¼ 592) in this study would benefit from treat-
ment. However, 49% (n ¼ 361) with asthma and
rhinitis were untreated, and only 72 untreatedYes % N/A %
48 25
27 41
hem? 31
ers? 19
have an attack? 22
1
85
40
questions about the asthma management provided by their
were not provided with a peak flow meter or were using
marked either Yes or N/A to the above questions.
oderate–severe
termittent
Moderate–severe
persistent
Total
84 128 389 (68%)
17 66 182 (32%)
01 (18%) 194 (34%) 571
sed rhinitis at the time of enrollment. Severity is classified
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Table 6 Rhinitis severity and current treatment.
Mild intermittent Mild persistent Moderate–severe
intermittent
Moderate–severe
persistent
Total
No treatment 125 50 53 111 339 (59%)
Antihistamine 55 21 37 43 156 (27%)
Antihistamine &
nasal steroids
16 5 9 28 58 (10%)
Nasal steroids 1 1 1 8 11 (2%)
Immunotherapy 0 0 0 3 3 (1%)
Other
treatment
2 0 1 1 4 (1%)
Total 199 77 101 194 571
Severity and treatment of rhinitis in 571 patients with physician-diagnosed rhinitis at the time of enrollment. Severity is
classified according to ARIA in 4 classes. Eleven patients received immunotherapy, 8 in combination with pharmacotherapy (not
shown in the table).
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which did not require daily treatment.
Sixty-eight patients with GINA 1 severity were
undertreated, i.e. no treatment was prescribed.
Patients with GINA 2–4 severity should be treated
with an anti-inflammatory agent. Thus, of the
patients with asthma, 76% (n ¼ 276) were under-
treated (i.e. untreated or treated only with b2-
agonists). Long-acting b2-agonists are recom-
mended for patients with GINA 3 and 4. Only
22 (4.5%) of all the asthmatics, were treated
accordingly.
Of the rhinitis patients, 339 (59%) were un-
treated and 244 (83%) with moderate to severe
rhinitis were undertreated (untreated or treated
only with antihistamines). Only 12 (2%) patients
were receiving allergen immunotherapy. Eleven
suffered from allergic rhinitis and one from mild
allergic asthma and rhinitis. After careful assess-
ment of each participant, we found that 12 (2%)
with allergic asthma, 219 (31%) with moderate–
severe rhinitis and 146 (21%) with both asthma
and rhinitis met the current indications for im-
munotherapy. On re-evaluating the asthma
and rhinitis treatment and diagnosis in all 726
participants at entry, 50% (n ¼ 361) subjects
were found to be untreated and 71% (n ¼ 513)
undiagnosed.Discussion
The objectives of the present study were to
evaluate the unawareness and undertreatment of
asthma or rhinitis among a general asthma andrhinitis patient population, and not to access the
frequency of respiratory diseases. One way to
approach the general population with non-acute
illness is by mail. In this way we were able to
perform a screening of a large general population
for relevant respiratory symptoms.
The prevalence of physician-diagnosed asthma
and rhinitis in Northern Europe is increasing and is
about 5–10% and 10–20%, respectively.1–3,23,24
Although, ours is not a true epidemiological study,
we found a frequency of 4.5% doctor-diagnosed
asthma and 5.2% doctor-diagnosed rhinitis patients.
This is lower than that reported previously in
questionnaire-based studies with self-reported
symptoms. Furthermore, we included only those
with a positive skin prick test, defined by a 5mm
weal, which is a higher threshold value compared
to epidemiological studies that generally define all
reactions above 3mm as significant for atopy.2,3
Thus, these frequencies based on a doctor-diag-
nosis rather than patient’s self-reported symptoms,
and lower skin test threshold values probably
reflect a true approximation of the current disease
burden.
The present study shows that about 50% of
patients with asthma or rhinitis are undiagnosed
and undertreated. This agrees with recent studies,
which report that less than half of those who were
classified as having doctor-diagnosed asthma had
been diagnosed as asthmatics by a physician
previously.10,25–27 In comparison to earlier studies
that report lower frequencies (3–11%) of undiag-
nosed asthma this study includes symptoms as
described in the GINA guidelines (including
cough as the sole symptom of asthma) and lung
function tests with methacholine challenges in
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number of subjects suspected of asthma and thus
lead to a higher frequency of undiagnosed asth-
matics, as compared to previous studies.28 How-
ever, it is important to note that we verified
symptoms of airway hyper-responsiveness by lung
function tests as well.
On the other hand, some caution should be
observed when interpreting these data. The re-
sponse rate was low and the data may not reflect
the true population in an epidemiological sense.
Then, to be considered is the patients’ motivation
to call the clinic for an appointment. This may
cause a selection bias with more symptomatic
undiagnosed and untreated patients at the clinic.
This may cause overestimation of the frequencies
and disease severities. Thirdly, the earlier diagnosis
was made on the patients’ own reports and under-
standing of the information given by their doctors.
Because of poor recall, lack of patient information/
education and understanding of the diseases may
have resulted in underreporting by the patients.
However, in their study, van den Boom and co-
workers29 found only 13% cases of diagnostic
misclassification.Why are patients undiagnosed?
It has been suggested that asthmatics with mild
disease are often not recognised as asthmatics by
their doctor. This does not seem to apply in the
present study, as the proportion of undiagnosed
asthmatics was higher in the severe disease
categories. It is generally accepted that most
asthma care should be provided at the primary
care level, but patients who may benefit from
consultation with a specialist should be identified
and referred accordingly. The high number of
patients with undiagnosed moderate to severe
persistent asthma in this study may suggest that
this recommendation is not being effectively
managed. This was confirmed by our finding that
60% of the patients had not seen a specialist
previously. However, 85% of the patients had
seen their doctor within 1 yr, which indicates
that this was not because of reluctance to seek
medical help. Considering that rhinitis and asthma
are associated disorders and 59% of our rhinitis
patients suffered from asthma they should have
been cheeked for asthma. In fact, the above
suggests that increased awareness among physi-
cians would provide an excellent opportunity for
the early detection of airflow obstruction and
rhinitis.Why do patients accept symptoms?
A large number of patients are symptomatic and
accept this. Several studies show that patients’
perceptions of their overall asthma control do not
match the severity of the symptoms they report.
We did not assess their self-perception of the
severity, but the study indicates that awareness
and knowledge were low and may be one reason for
accepting the symptoms. Although, 60% of the
patients with known asthma had seen an asthma
specialist before entering the study the data
indicate that those patients were not adequately
trained about their asthma and treatment. More-
over, current smoking was high (49%) among
asthmatics and perhaps the asthma symptoms were
simply overlooked or neglected and thus accepted
by the patients.Why are patients undertreated?
Almost 40% of patients with moderate to severe
asthma were not receiving anti-inflammatory treat-
ment. These patients are at risk of acute exacer-
bation. Our results of corticosteroid usage rates
agree with recent studies reporting suboptimal use
of inhaled corticosteroids in patients with mild to
severe persistent asthma. Another important find-
ing in our study was that use of long-term b2-
agonists was strikingly low and bronchodilator
therapy for quick relief was inappropriately high
in relation to the use of inhaled corticosteroids and
the severity of the asthma symptoms. This con-
forms with recent European studies showing an
inappropriate ratio of inhaled corticosteroids to
short-acting bronchodilators.30–33 Although more
than half of our patients had been instructed in the
handling of their asthma devices a high number of
patients were self-taught. Moreover, the data
demonstrated inadequate monitoring of lung func-
tion by peak flow. In addition, written management
plans were virtually non-existent. This implies that
perhaps the asthma management guidelines are not
being adequately put in practice by physicians and
patients.
The management of allergic rhinitis includes
avoidance of allergens, medication, and immu-
notherapy. Patients with moderate–severe symp-
toms should be treated with intranasal
corticosteroids and immunotherapy should be
considered. Patients with allergic rhinitis and
seasonal asthma are likely candidates for immu-
notherapy. Considering that optimal management
of rhinitis may partly improve coexisting asthma, it
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and rhinitis were untreated. Furthermore, 21%
received treatment for rhinitis but not for asthma.
Immunotherapy may prevent occurrence of asth-
ma in patients with moderate to severe rhinitis.34
The very low number of patients on immunotherapy
thus indicates that very little attention has been
paid to this type of treatment.
An initial definition of the patients’ allergic
status will affect therapeutic decisions. Less than
half of the patients with a known allergy had
previously been diagnosed as such. This increases
the likelihood of non-compliance on the part
of the patient who does not understand the
rationale behind the treatment, follow-up, and
appropriate alterations in the therapeutic plan.
This may also explain why the majority of our
patients did not have a better understanding of
how to recognise and avoid external/internal
precipitants with the potential to induce or
aggravate symptoms.
In conclusion, the study was undertaken to assess
the current status of diagnosis and treatments for
asthma and allergic rhinitis after the promotion and
publication of GINA and ARIA guidelines. This study
indicates that despite increased knowledge, pub-
lication of guidelines, improved drug treatment,
increased awareness, and education of primary
care physicians the diagnosis and treatment of
patients with asthma and rhinitis are insufficient.
Thus, further measures must be considered. Possi-
bly patient education must be improved and public
awareness should be increased. Further efforts
must be made to improve management of asthma
and rhinitis in general practice.References
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